Evaluation of the relationship between IL-10, IL-17, IL-23 levels and disease activity of systemic lupus erythematosus and vitamin D status

Yıl 2021, Cilt: 1 Sayı: 1, 25 - 30, 30.04.2021

Beyza Genç Çetin Taşkın Şentürk Neriman Aydın

https://doi.org/10.26900/hsq.1.1.05

Öz

Systemic lupus erythematosus (SLE) is a multisystemic, autoimmune connective tissue disease with a variable course and prognosis. We intended to determine IL-10, IL-17 and IL-23 cytokines and vitamin D levels in SLE patients, which we think play role in the pathogenesis of the disease. Forty SLE patients and 20 healthy controls were included in our study. Levels of IL-10, IL-17 and IL-23 were measured by sandwich ELISA method. Quantitative data are expressed as mean ± Standard deviation and median range (maximum-minimum) values. The data were analyzed at 95% confidence interval, and cases where the p value was less than 0.05 were considered statistically significant. IL-10 and IL-17 levels of the control and patient groups were compared and no significant difference was found (p=0.333, p=0.99). IL-23 levels of the patient group were found to be higher than the control group and were found to be statistically significant (p<0.001). No significant relationship was found between disease duration or SLEDAI score and IL-23 levels(p=0.476). 25 (OH) vitamin D levels of the patient group were found to be lower than the control group and were statistically significant (p=0.003). No significant relationship was found between IL-10 and IL-17 levels and vitamin D. Significant relationship was found between IL-23 and vitamin D levels (p=0.019). In our study, there was no significant difference between the groups in terms of IL-10 or IL-17, while IL-23 levels were found to be significantly higher in SLE patients. Vitamin D levels were found to be lower in the patient group with SLE compared to the control group, and a negative correlation was found between the disease duration and IL-23. Specific blocking of the IL-23 immune pathway can be an effective and safe treatment option in the treatment of SLE

Anahtar Kelimeler

Systemic lupus erythematosus, IL-10, IL-17, IL-23, Vitamin D

Kaynakça

• HOCHBERG, M.C., SILMAN, A.J., SMOLEN, J.S., WEINBLATT, M.E., WEISMAN, M.H., eds., 2011, Rheumatology, Connective Tissues Disorders, 5th edition, Mosby Elsevier, Philadelphia, 1223-1334.
• YAP, D.Y., LAI, K.N., 2013, The role of cytokines in the pathogenesis of systemic lupus erythematosus – from bench to bedside, Nephrology, 18 (4), 243-255.
• LOURENÇO, E.V., LA CAVA, A., 2009, Cytokines in Systemic Lupus Erythematosus, Current Molecular Medicine, 9 (3), 242-254.
• PENG, H., WANG, W., ZHOU, M., et al., 2013, Role of interleukin-10 and interleukin-10 receptor in systemic lupus erythematosus, Clinical Rheumatology, 32 (9), 1255-1266.
• CHEN, S., SIMS, G.P., CHEN, X.X., et al., 2007, Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation, Journal of Immunology, 179 (3), 1634-1647.
• BOONSTRA, A., BARRAT, F.J., CRAIN, C., et al., 2001, 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells, Journal of Immunology, 167 (9), 4974-4980.
• HOCHBERG, M.C., 1997, Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus, Arthritis and Rheumatism, 40 (9), 1725.
• BOMBARDIER, C., GLADMAN, D.D., UROWITZ, M.B., et al., 1992, The Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: A disease activity index for lupus patients. Arthritis and Rheumatism, 35 (6), 630-640.
• WASZCZYKOWSKA, E., ROBAK, E., WOZNİACKA, A., et al., 1999, Estimation of SLE activity based on the serum level of chosen cytokines and superoxide radical generation, Mediators of Inflammation, 8 (2), 93-100.
• WONG, C.K., LIT, L.C., TAM, L.S., et al., 2008, Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity, Clinical Immunology, 127 (3), 385-393.
• VAN VOLLENHOVEN, R.F., HAHN, B.H., TSOKOS, G.C., et al., 2018, Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study, Lancet, 392 (10155), 1330-1339.
• SHAHIN, D., EL-FARAHATY, R.M., HOUSSEN, M.E., et al., 2017, Serum 25-OH vitamin D level in treatment-naïve systemic lupus erythematosus patients: Relation to disease activity, IL-23 and IL-17, Lupus, 26 (9), 917-926.
• ARICAN, O., ARAL, M., SASMAZ, S., et al., 2005, Serum levels of TNF alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity, Mediators of Inflammation, 2005 (5), 273-279.